Xontogeny is a Boston-based life sciences accelerator and investment firm focused on building companies from early development through clinical proof of concept. Its model combines seed investing with hands-on strategic and operational support, often in conjunction with larger follow-on financing through the broader Perceptive ecosystem. It is designed for science-driven founders who need significant help shaping a company, not just funding a round.

Its portfolio includes neuro-focused and device-related companies such as CereVasc and Neurosterix. Xontogeny is especially relevant to early-stage healthcare and neuroscience businesses that need experienced company-building support, leadership recruitment, and development planning. It occupies a useful middle ground between incubator and institutional life sciences investor.

The firm focuses mainly on North America, with selective European reach. For neurotech founders, it is most relevant where the company is therapeutics-heavy, clinically serious, or still needs major operational shaping. It is a strong option for founders building early life sciences and neuro-focused companies who want deeply engaged support.